Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO
Former TAP Partner
DUBLIN, May 12, 2022 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present abstracts on Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – June 7, 2022.
Highlights from Jazz and its investigational sponsors at the congress feature data for JZP351 across a range of hematological malignancies:
- Two poster presentations for JZP351 including preliminary results from Arm B (JZP351 in combination with midostaurin) from the Phase 1b V-FAST trial in adults with previously untreated FLT3-mutated acute myeloid leukemia (AML) and data from the Phase 1b trial evaluating lower-intensity JZP351 + venetoclax in adults with newly diagnosed AML who are unfit for intensive chemotherapy.
|
Presentation Title |
Author |
Presentation Details |
|
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia |
McCloskey J, et al. |
Type: Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 4 at 9:00 a.m. EDT Abstract number: 7043 |
|
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy |
Uy G.L. et al. |
Type: Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 4 at 9:00 a.m. EDT Abstract number: 7031 |